来自:中国糖尿病杂志 编辑:董闪闪 张洁 刘皤等|点击数:|2016-02-28
【摘要】 目的 探讨α-辛酸(ALA)对不同程度糖尿病慢性肾脏疾病(CKD)患者尿足细胞标志蛋白(PCX)及VEGF的影响。 方法 186例T2DM患者根据UAER分为单纯糖尿病组(SDM组)、尿白蛋白微量组(NA组)、尿白蛋白大量组(MA组),NA组和MA组又分为ALA治疗组(NA工组,MA I组)及常规治疗组(NAⅡ组,MAlI组)。另选正常对照者(NC组)60名。比较各组ALA治疗前及治疗2周后尿PCX及血VEGF。结果 NAI组ALA治疗后PCX[(17.65±3.05)vs(7.28±2.93)/ug/L,P<0.01],VEGF[(453.94±36.17)VS(356.39±47.08)ng/L,P<001]下降,MA I组ALA治疗后PCX[(265±51)vs(119.9±2.22)pg/L,P<0.01],VEGF[(550.65±46.76)vs(397.69±44.74)ng/L,P
d0.01)]下降。 结论 ALA可通过抗氧化应激(0S)保护肾小球足细胞。
【关键词】 糖尿病慢性肾脏疾病;α-硫辛酸;尿足细胞标志蛋白;血管内皮生长因子
【Abstract】 Objective To investigate the effect of α-lipoic acid(ALA)On urinary podocalyxin (PCX)and vascular endothelial growth factor(VEGF)in different stages of chronic kidney disease(CKD) in diabetes. Methods A total of 246 participants were divided into four groups according tO their UAER:normal control group(NC,n=60),simple diabetes mellitus without nephropathy group(SDM,n=62),micro albuminuria group(NA,n=60)and macro albuminuria group(MA,n=64).NA and MA groups were also randomly divided into two groups:ALA treatment group(NA I,MA I)and conventional treatment group(NAⅡ,MA 1I).The 1evels of urinary PCX and serum VEGF were determined at baseline and after 2 weeks’treatment. Results The levels of urinary PCX and serum VEGF were 10wer after ALA treatment than before ALA treatment in NA I[(17.65±3.05)vs(7.28±2.93) μg/L(453.94±36.17)vs (356.39±47.08) ng/L;P<0.01] and MA I[(26.95±5.41)vs(11.99±2.22)μg/L;(550.654±46.76) vs (397.69±44.74)ng/L,P<0.01)]groups respectively. Conclusion ALA can protect glomerular podocyte from injury,possibly due to its effects on alleviating enhancedoxidative stress(OS).
【Key words】 Chronic kidney disease(CKD)in diabetes;α-lipoic acid(ALA);Urinary podocalyxin
(PCX):Vascular endothelial growth factor(VDGF)
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想